Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
13,696 total articles
Apple is not trying to race to build the largest foundation models. Instead it is embedding smarter AI into devices and services where it already wins: privacy-first on-device features, tighter ecosystem lock-in, and higher-margin services. The balance sheet, cash generation, and services profitability give Apple room to monetize AI on its terms. T…
Apple's combination of high-margin services, accelerating AI-enabled accessories (HomeView launch), and a fortress balance sheet make a clear case for upside to a $6 trillion market cap. This trade lays out an actionable entry, stop, and target with timeline and risk controls — a long-term (180 trading days) position with checkpoints tied to produc…
Palantir is rallying into strong fundamentals: $501B market cap, positive free cash flow, high retention and a growing AI platform. The market still prices perfection (P/S ~81, P/E ~166), but the company’s backlog, government moat, and accelerating commercial AI adoption justify a constructive stance. This trade idea outlines an entry, stop, target…
Innodata has fallen roughly 50% from its 52-week high but is reporting accelerating AI-driven revenue, strong free cash flow and improving operating metrics. The market has punished the stock’s premium multiple; we view that as an opportunity for a mid-term swing aimed at a re-rating if execution continues and commercial pilots convert to recurring…
Takeda trades near $18.50 with a $59B market cap, a 3.1% yield and a reorganized R&D slate that just added a narcolepsy approval. The combination of cash-generative legacy franchises, milestone upside from partnered assets and an improving biotech collaboration footprint make the stock a buy into a 180-trading-day target of $22.00. Use a strict sto…
HubSpot (HUBS) has been pummeled this year amid pricing-change angst and customer-addition headlines. The pullback has left the stock trading near $221 with free cash flow of $797.5M and an FCF multiple near 14x. For disciplined buyers, this is an accumulation opportunity with defined entry, stop, and target levels across short-, mid-, and long-ter…
Sandisk (SNDK) has been a standout beneficiary of the AI memory supercycle, but price action and technicals show a fresh top formation. With bearish momentum, an upcoming 10/29/2026 earnings event, and renewed headlines about Chinese competition, we outline a tactical short: entry at $1456, stop at $1700, target $1100, mid-term (45 trading days) vi…
Buy Microsoft for a mid-term re-rate tied to Azure AI commercialization and enterprise adoption of Copilot; trade plan provided with entry, stop, and targets. The thesis is pragmatic: Microsoft can deliver steady AI-driven top-line improvements and margin leverage separate from raw GPU tailwinds, offering a lower-volatility way to own AI exposure w…
Medpace (MEDP) is trading like a growth business whose pipeline is collapsing. In reality, recent booking cleanup, legal overhang and premium multiples create a better short opportunity than a buy. I recommend a short entry at $620.05 with a target of $520.00 and a stop at $655.00 on a mid-term (45 trading days) horizon.
Xerox (XRX) is showing the early pieces of a turnaround: positive free cash flow, an EV/EBITDA in the mid-single digits, and a bounce from multi-month lows. The combination of fundamental cheapness and a technical base supports a speculative long with clearly defined risk controls. This trade idea outlines entry, stop and target for a mid-term (45 …
Taiwan Semiconductor (TSM) remains the cornerstone of the AI-era chip supply chain. Recent top-line acceleration and aggressive capacity expansion for premium nodes justify a 'Strong Buy' stance. This trade idea lays out an entry at $444.00, a stop at $420.00 and a primary target of $520.00 over a 180-trading-day horizon while framing upside driver…
AST SpaceMobile (ASTS) has been punished for execution and competitive fears, sliding to a 52-week low near $46.23. That weakness appears priced for worst-case outcomes: large dilution, failed customer adoption and no path to revenue. The facts on liquidity ($3.7B reported), signed operator deals and a falling RSI argue the selloff may be overstate…
HCA Healthcare (HCA) looks priced for resilience, not disappointment. Strong free cash flow, a sub-10x EV/EBITDA multiple and a still-reasonable P/E support a mid-term long trade despite recent headwinds to payer mix. Enter at current levels with a $520 target and a $430 stop; the trade leans on operational improvements and consistent cash generati…
ASML remains the dominant supplier of extreme ultraviolet (EUV) lithography and benefits from multi-year visibility into customer capex. With Q3 approaching, we prefer a tactical long that buys the stock into uncertainty while capping downside. This is a conviction trade that leans on order backlog resiliency and services revenue growth.
NovoCure (NVCR) trades below peers on headline multiples while still generating recurring device revenue from its Optune platform. With a $1.67B market cap, positive regulatory momentum (Optune Pax approval for pancreatic cancer), and elevated short interest, the risk/reward favors a long trade into the next 180 trading days. Entry $14.25, target $…
TELUS appears to have absorbed recent one-off charges and is now trading like a low-growth utility while its wireless and health businesses have optionality. This trade targets a mid-term re-rating as operational clarity and modest upside catalysts re-ignite investor interest.
Avista (AVA) trades near its 52-week low on the back of negative free cash flow and elevated leverage, yet the utility offers a 5.49% yield, a P/E near 13 and a price-to-book around 1.06. If management stabilizes financing and rate cases largely hold, the stock can re-rate toward prior highs. This trade idea lays out entry, stop and target for a lo…
Vylor Inc. (VYLR) provides agricultural and crop production services and is trading near its 52-week high at $74.92 with a market cap near $50.0B. High short activity, a modest PB of 2.01 and a forward-looking narrative tied to food scarcity make this a tactical long idea. Entry, stop and target are specified with a mid-term horizon and clearly def…
South Bow (SOBO) offers a rare mix for income-focused traders: a 6% yield, mid-teens P/E and a tangible pipeline footprint connecting Alberta crude to U.S. refineries. We lay out a concrete trade with entry, stop and target for a long-term trade window (180 trading days) that balances dividend income with upside tied to operational recovery, regula…
Marvell is my top pick in the connectivity layer of AI infrastructure. The company already shows accelerating data-center revenue, attractive operating margins, and management has laid out aggressive revenue targets that imply a multi-decade market opportunity. Today’s pullback offers a concrete entry at $260.10 with asymmetric upside if Marvell ex…
Kraken Robotics (KRKNF) makes sensors, subsea batteries and AUV systems for naval and energy customers. Recent order wins and a sizable financing tempered by volatile OTC trading have pushed the stock down to $3.04 despite accelerating revenue and improving adjusted EBITDA. We see a tactical long with entry at $3.04, stop at $2.70 and a primary tar…
Discovery Silver (DSVSF) is trading near $8.40 with a market cap of roughly $6.9B and a clear, single-asset development story in the Cordero silver project. The setup today is a tactical long: technicals are neutral, fundamentals justify a premium versus peers, and near-term catalysts could re-rate the stock. I outline a mid-term (45 trading days) …
Procter & Gamble's portfolio is showing early signs of margin recovery and volume stabilization while cash flow remains robust. With a market cap near $355B and a forward multiple in the low-20s, the stock looks actionable on a mid-term horizon around upcoming earnings and execution milestones. This trade sets a clear entry, stop and target and out…
Calumet (CLMT) trades near its 52-week high despite negative EPS, high EV/EBITDA and recent operational headlines. With an upcoming quarterly print likely to highlight ongoing renewables downtime and pressure in Performance Brands, we lay out a mid-term short trade with clear entry, stop and target levels.
Shares plunged after an acquisition proposal failed to close. The market is punishing optionality rather than core operations: MGM still generates meaningful free cash flow, trades at low EV multiples, and has operational tailwinds in BetMGM and Macau. This is a tactical long trade on mean reversion with explicit stops and a mid-term horizon.
